{Reference Type}: Case Reports
{Title}: Durable Response to Maintenance Treatment Comprised of Viagenpumatucel-L, Nivolumab, Ramucirumab, and Docetaxel in a PD-L1-Low Advanced-Stage Non-Small-Cell Lung Cancer: A Case Report.
{Author}: Gollard R;Arana B;Kaltenbrun E;Tebbey P;
{Journal}: Case Rep Oncol
{Volume}: 16
{Issue}: 1
{Year}: 2023 Jan-Dec
暂无{DOI}: 10.1159/000530132
{Abstract}: Checkpoint inhibitors (CIs) are now standard of care for late-stage non-small-cell lung cancer (NSCLC); however, only a minority of patients treated with a CI show clinical benefit compared to platinum-based chemotherapy alone, regardless of programmed cell death ligand 1 (PD-L1) expression levels. We describe a case of durable tumor response and disease stabilization in a patient with advanced pretreated squamous NSCLC given a maintenance treatment comprised of nivolumab, docetaxel, and ramucirumab combined with the allogeneic cellular cancer vaccine viagenpumatucel-L over a period of 28 months. Our case suggests that combination strategies that serve to sensitize tumors to checkpoint inhibition, even in patients refractory to available treatment, may lead to improved efficacy.